Clonal Cytopenias of Undetermined Significance (CCUS) — Expert Haematology Monitoring & MDS Risk Evaluation

CCUS stands for Clonal Cytopenias of Undetermined Significance. It describes a condition where a person has two findings at the same time: (1) persistently low blood counts (cytopenia) in one or more blood cell types — below defined thresholds for more than 4 months — that cannot be explained by any obvious cause such as vitamin deficiency, infection, or medication; and (2) detectable mutations in blood stem cell genes (clonal haematopoiesis) on genetic testing. Crucially, CCUS does NOT meet the diagnostic criteria for myelodysplastic syndrome (MDS) or any other blood cancer — it sits in a pre-malignant 'grey zone' with elevated but not certain risk of progressing to MDS over time.

MDS (myelodysplastic syndrome) is a blood cancer where the clonal changes are severe enough to meet formal diagnostic criteria: either ≥10% of cells in at least one blood lineage in the bone marrow show abnormal appearance (dysplasia), or there are specific genetic changes, or the bone marrow blast count is elevated. In CCUS, the bone marrow looks close to normal and these MDS thresholds are not met — even though mutations and cytopenia are present. This distinction is not always easy to make, which is why expert bone marrow biopsy review by a specialist haematopathologist is essential. The reason it matters is that MDS requires active treatment, while CCUS is managed with watchful waiting and surveillance.

The risk of CCUS progressing to a diagnosable myeloid neoplasm (mainly MDS, occasionally AML) is approximately 10–15% per year — significantly higher than the ~1% annual risk for CHIP (clonal mutations without cytopenia) and ~5% for ICUS (cytopenia without clonal mutations). This means that over 5 years, approximately 50% of CCUS patients will develop MDS. However, this risk is not uniform — it depends heavily on the specific mutations present. High-risk mutations such as TP53 or multiple co-occurring mutations carry much higher annual progression rates, while single low-risk mutations (TET2, DNMT3A) carry lower rates.

The most commonly identified mutations in CCUS occur in genes that regulate DNA methylation, chromatin remodelling, and RNA splicing. The most frequent are: TET2 and DNMT3A (epigenetic regulators — most common, relatively lower risk); ASXL1 (chromatin modifier — intermediate risk); SF3B1, SRSF2, and U2AF1 (RNA spliceosome genes — associated with higher MDS progression risk); and IDH1/IDH2 (metabolic enzymes — associated with AML risk). TP53 mutations, while less common in CCUS, carry the highest progression risk. The precise mutation — combined with variant allele fraction and co-occurring mutations — determines the individual patient's risk level.

Currently there is no approved treatment that modifies the underlying clonal process in CCUS or has been proven to prevent progression to MDS. Management focuses on: (1) treating the symptoms of cytopenia — blood transfusions for anaemia, growth factors for severe neutropenia; and (2) structured surveillance with regular blood counts and periodic bone marrow biopsies to detect MDS progression early. For patients with high-risk CCUS (TP53, spliceosome mutations, or multiple co-occurring mutations), enrolment in clinical trials evaluating preemptive hypomethylating agent therapy (azacitidine, decitabine) or venetoclax is the most impactful currently available option.

Monitoring frequency depends on the risk profile. Low-risk CCUS (single TET2 or DNMT3A mutation, mild stable cytopenia): blood count review every 3–6 months and bone marrow biopsy every 12–18 months. Intermediate risk (spliceosome mutations, moderate cytopenia): blood count every 2–3 months and bone marrow every 6–12 months. High-risk CCUS (TP53, multiple mutations, severe cytopenia, rising VAF): blood count every 4–6 weeks and bone marrow biopsy every 3–6 months. Any sudden deterioration in blood counts — regardless of scheduled monitoring — triggers an immediate bone marrow assessment.

CHIP (Clonal Haematopoiesis of Indeterminate Potential) is defined by detectable clonal mutations in myeloid genes at a variant allele fraction ≥2% in a person with completely NORMAL blood counts and no haematological diagnosis. CHIP is common (affecting approximately 10–20% of adults over 70) and carries a low (~1% per year) risk of progressing to a blood cancer. CCUS has the same clonal mutations BUT also has unexplained persistent cytopenia. The addition of cytopenia substantially increases the progression risk to ~10–15% per year and means the patient requires specialist haematology surveillance rather than routine monitoring.

No. A bone marrow biopsy is an essential component of CCUS diagnosis. It is required to: (1) confirm that the bone marrow does NOT meet diagnostic criteria for MDS (ruling out ≥10% dysplasia, ring sideroblast thresholds, blast increase, or defining cytogenetic abnormalities); and (2) assess bone marrow cellularity, architecture, and iron stores. Without a bone marrow biopsy, the distinction between CCUS and MDS cannot be made, and the diagnosis of CCUS cannot be assigned. Expert haematopathologist review of the biopsy is particularly important, as subtle MDS features can be missed in non-specialist settings.

Yes. CancerFax connects CCUS patients with specialist haematologists and MDS research experts who provide expert bone marrow biopsy review to confirm or reclassify the CCUS diagnosis, NGS mutation profile interpretation and risk stratification, structured surveillance protocol guidance, second opinion coordination for borderline bone marrow findings, and identification of and referral to clinical trials evaluating preemptive intervention in high-risk CCUS. We work with specialist haematology centres in India, Germany, South Korea, the UAE, and other countries to connect patients with the most appropriate expert care for this pre-malignant clonal haematopoiesis condition.